

70332 U.S. PTO
08/951733
10/16/97
Class Subclass
ISSUE CLASSIFICATION
SCANNED

UTILITY SERIAL NUMBER	PATENT DATE	PATENT NUMBER
-----------------------------	-------------	------------------

SERIAL NUMBER 08/951,733	FILING DATE 10/16/97	CLASS 435	SUBCLASS 193	GROUP ART UNIT 1634 1653	EXAMINER Burgin
-----------------------------	-------------------------	--------------	-----------------	--------------------------------	--------------------

APPLICANTS LEA ANNE HARRINGTON, TORONTO, CANADA; MURRAY O. ROBINSON, MAILBU, CA.

CONTINUING DATA***
VERIFIED

285 CIP OF 08/873039 6/11/97 ABN
CIP 08/751,189 11/15/96 5 (PND) 12/8

FOREIGN APPLICATIONS***
VERIFIED

FOREIGN FILING LICENSE GRANTED 02/04/98

Foreign priority claimed 35 USC 119 conditions met	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no	AS FILED	STATE OR COUNTRY CAX	SHEETS DRWGS. 46	TOTAL CLAIMS 32	INDEP CLAIMS 14	FILING FEE RECEIVED \$2,086.00	ATTORNEY'S DOCKET NO. A-433B
---	---	-------------	----------------------------	------------------------	-----------------------	-----------------------	--------------------------------------	------------------------------------

US PATENT OPERATIONS NOA
NO 404 B BARRER INC
AMGEN CENTER
4840 DE HAVILLAND DRIVE
THOUSAND OAKS CA 91320-1789
*Dept 4300 MS 27-4A
One Amgen Center Drive*

TITLE NOVEL GENES ENCODING TELOMERASE PROTEINS

U.S. DEPT. OF COMM./PAT. & TM - PTO-436L (Rev. 12-94)

PARTS OF APPLICATION FILED SEPARATELY		Applications Examiner	
NOTICE OF ALLOWANCE MAILED		CLAIMS ALLOWED	
		Total Claims	Print Claim
ISSUE FEE		DRAWING	
Amount Due	Date Paid	Sheets Drwg.	Figs. Drwg.
		Print Fig.	
Label Area		ISSUE BATCH NUMBER	
		PREPARED FOR ISSUE	
WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.			

Form PTO-436A
(Rev. 8/92)
SCAN 1 omw
QC 8/2

BEST AVAILABLE COPY